We fractionated, by gel chromatography, sera with high IgE content from atopic subjects and five cases with the hyper-IgE syndrome, and measured the presence of IgE in high molecular weight (HMW) fractions. Two out of four asthmatics and four out of five hyper-IgE had HMW IgE. The same serum fractions gave positive results for conglutinin binding IgG (all six) and IgA (three cases) as well as C1q binding complexes (five cases). IgG auto-antibodies to IgE were also detected together with IgE in HMW fractions. Anti-F(ab)'2 activity was present in five cases (one of them negative for IgG anti-IgE). Our data indicate that complexes made of IgE and IgG anti-IgE are present mainly in patients with chronic allergic symptoms and most frequent in cases of hyper-IgE syndrome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2222.1986.tb01989.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Utility of serum biomarkers in real-world practice for predicting response to omalizumab therapy in patients with chronic spontaneous urticaria.
J Allergy Clin Immunol Glob
February 2025
Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, Cincinnati, Ohio.
Background: Omalizumab (OMA), a recombinant humanized IgG monoclonal anti-IgE antibody, is approved for treatment for chronic spontaneous urticaria (CSU) refractory to second-generation H-antihistamine (SGAH) therapy. However, currently, there are no validated serum biomarkers to reliably predict response to OMA treatment.
Objective: We explored the real-world clinical utility of using serum biomarkers for predicting response to OMA for CSU patients with disease refractory to high-dose SGAH therapy.
High IgG Anti-IgE Autoantibodies Prevent Early Omalizumab Response in Chronic Spontaneous Urticaria.
Allergy
December 2024
Center for Allergy, Nihon University School of Medicine, Tokyo, Japan.
Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions.
Allergol Select
November 2024
Institute of Allergology, Charité Universitätsmedizin Berlin und Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin.
Article Synopsis
- Targeted therapies using biologics for atopic diseases, urticaria, and angioedema are advancing quickly, with several new antibodies developed, tested, and approved for clinical use, like omalizumab and dupilumab.
- There is ongoing research into combining different biologics for enhanced treatment efficacy, expanding their applications to conditions like food allergies and eosinophilic esophagitis.
- There are emerging concerns about unexpected side effects and hypersensitivity reactions associated with these therapies, raising important questions about their safety and mechanisms, particularly in specific patient groups like children.
Severe chronic spontaneous urticaria responding and not responding to omalizumab: analysis of the prognostic value of known and novel in-vitro variables.
Eur Ann Allergy Clin Immunol
November 2024
Department of Pathophysiology and Transplantation, Università Degli Studi di Milano, Milan, Italy.
Chronic spontaneous urticaria (CSU) response to anti-IgE treatment can be rapid, late or absent. Recently, potential mechanisms of activation of mast cells alternative to FceRI, including mas-related G protein-coupled receptor X2 (MRGPRX2), activation of coagulation cascade, and activation of eosinophils have been described. We measured several potential in-vitro markers, including well-known MRGPRX2 activators, in sera of patients CSU both responding and not responding to omalizumab.
View Article and Find Full Text PDFChronic Spontaneous Urticaria: A Review.
JAMA
November 2024
Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Article Synopsis
- * Diagnosis is usually made based on recurring symptoms like wheals and angioedema, and it often lasts over a year; around 40% of patients experience significant negative effects on their quality of life.
- * First-line treatment includes second-generation H1 antihistamines, with about 40% of patients showing improvement, while omalizumab is recommended for those not responding to antihistamines, although 30% may not benefit; cyclosporine is another option with some effectiveness but potential side
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!